NF-κB–dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity-Reference-Cited by-同舟云学术

NF-κB–dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity

Published:2021-07-29 Issue:61 Volume:6 Page:
ISSN:2470-9468
Container-title:Science Immunology
language:en
Short-container-title:Sci. Immunol.

Author:

Ghislat Ghita¹^ORCID,Cheema Ammar S.¹,Baudoin Elodie¹,Verthuy Christophe¹,Ballester Pedro J.²,Crozat Karine¹^ORCID,Attaf Noudjoud¹^ORCID,Dong Chuang¹^ORCID,Milpied Pierre¹^ORCID,Malissen Bernard¹^ORCID,Auphan-Anezin Nathalie¹^ORCID,Manh Thien P. Vu¹^ORCID,Dalod Marc¹^ORCID,Lawrence Toby¹³⁴^ORCID

Affiliation:

1. CNRS, INSERM, Centre d’Immunologie de Marseille-Luminy (CIML), Turing Center for Living Systems, Aix-Marseille University, 13009 Marseille, France.

2. Cancer Research Center of Marseille CRCM, INSERM, Institut Paoli-Calmettes, Aix-Marseille University, CNRS, 13009 Marseille, France.

3. Centre for Inflammation Biology and Cancer Immunology, Cancer Research UK King’s Health Partners Centre, School of Immunology and Microbial Sciences, King’s College London, London SE1 1UL, UK.

4. Henan Key Laboratory of Immunology and Targeted Therapy, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, China.

Abstract

NF-κB and IRF1 coordinate intratumoral cDC1 maturation and control of immunogenic tumor growth.

Funder

H2020 Marie Skłodowska-Curie Actions

Agence Nationale de la Recherche

Institut National Du Cancer

Ligue Nationale contre le Cancer

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine,Immunology

Reference59 articles.

1. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy

2. Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

3. PD-1 blockade-driven anti-tumor CD8+ T cell immunity requires XCR1+ dendritic cells;Mao T.;bioRxiv,2020

4. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?

5. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8α+ dendritic cells

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. STING-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy;Bioactive Materials;2024-12

2. In vivo dendritic cell reprogramming for cancer immunotherapy;Science;2024-09-05

3. Applications of single-cell technologies in drug discovery for tumor treatment;iScience;2024-08

4. Extracellular Vesicle‐Inspired Minimalist Flexible Nanocapsules Assembled with Whole Active Ingredients for Highly Efficient Enhancement of DC‐Mediated Tumor Immunotherapy;Advanced Healthcare Materials;2024-07-25

5. Versatile function of NF-ĸB in inflammation and cancer;Experimental Hematology & Oncology;2024-07-16